Skip to main content
TipRanks
Go Ultimate75% OFF

Lisata Therapeutics (LSTA) Stock Price & Analysis

1,060 Followers

LSTA Stock Chart & Stats

$1.21-$0.07(-5.47%)
At close: 4:00 PM EST
$1$1.25$1.5$1.75Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.20 - $1.26
52-Week Range
$0.96 - $5.07
Previous Close
$1.28
Volume
N/A
Average Volume (3M)
136.60K
Market Cap
$13.07M
Enterprise Value
$306.11M
Total Cash (Recent Filing)
$282.72M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.27
Next Earnings
N/A
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Funding Runway

The approximately $225 million financing materially extends the company’s operating runway and supports advancement of MAR001/005 and MAR002 through Phase 2 milestones. This reduces immediate financing pressure and gives management more time to pursue clinical and regulatory value creation.

Low Leverage

Zero reported debt limits fixed financial obligations and reduces balance-sheet risk while the company funds clinical development. Low leverage preserves flexibility to deploy capital toward research, trials, and partnerships without adding interest costs or refinancing exposure.

Strategic Repositioning

The Marea transaction gives Lisata a broader cardioendocrine portfolio and experienced biopharmaceutical leadership, shifting the company toward Phase 2 programs with defined development milestones. That strategic reset may improve focus and strengthen execution capabilities over the medium term.

Bears Say

Persistent Cash Burn

Sustained negative operating and free cash flow shows that the business is not yet self-funding. Continued clinical investment therefore depends on external capital, making financial progress sensitive to financing needs even after the latest capital raise.

Minimal And Declining Revenue

Very small and declining revenue provides little evidence of current commercial scale or operating leverage. With revenue falling while expenses remain substantial, Lisata must rely primarily on future clinical success rather than an established revenue base to support sustainable profitability.

Dilution Risk

The acquisition financing substantially changes the ownership structure and creates potential dilution for legacy shareholders when preferred securities convert. Large equity plans and additional share issuance can also reduce each existing holder’s participation in future clinical or corporate upside.

Lisata Therapeutics News

LSTA FAQ

What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $0.96 and its highest was $5.07 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $13.07M.
When is Lisata Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.729 earnings per share for the quarter.
Is Lisata Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics pays a dividend of $0.31 which represents an annual dividend yield of ―. See more information on Lisata Therapeutics dividends here
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 10,804,066 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.729 in its last earnings report. Following the earnings report the stock price went down -6.509%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Hedge funds hold Lisata Therapeutics shares: the largest hedge-fund position in Lisata Therapeutics is 72,329,884 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology